Inno, Alessandro <br/><br/>
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?  [electronic resource] 

 -  Clinical colorectal cancer  Dec 2011 
 - 325-32 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1938-0674 
<br/><br/><label>Standard No.: </label>10.1016/j.clcc.2011.03.028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--genetics<br/>Cetuximab<br/>Colorectal Neoplasms--drug therapy<br/>DNA, Neoplasm--genetics<br/>Drug Resistance, Neoplasm<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Immunoenzyme Techniques<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Neoplasm Metastasis<br/>PTEN Phosphohydrolase--genetics<br/>Polymerase Chain Reaction<br/>Prognosis<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins c-met--metabolism<br/>Proto-Oncogene Proteins p21(ras)<br/>Receptor, IGF Type 1--metabolism<br/>Retrospective Studies<br/>Survival Rate<br/>ras Proteins--genetics